The Design Of Phase I Oncology Studies

This whitepaper explores the advantages and Model-based Designs in oncology phase I clinical trial design and provides an explanation as to why some clinical development teams and statisticians may have witnessed a slow update to this design method.

This Whitepaper will provide you with:

• The challenges of oncology clinical trials design
• Understanding of the Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT)
• Key understanding of Model-based and Rule-based Designs 
• Knowledge of why to use Model-based or Rule-based Designs
• The limitations of using Model-based Designs